David Baker

21.0k total citations · 3 hit papers
296 papers, 15.4k citations indexed

About

David Baker is a scholar working on Pathology and Forensic Medicine, Immunology and Molecular Biology. According to data from OpenAlex, David Baker has authored 296 papers receiving a total of 15.4k indexed citations (citations by other indexed papers that have themselves been cited), including 94 papers in Pathology and Forensic Medicine, 93 papers in Immunology and 86 papers in Molecular Biology. Recurrent topics in David Baker's work include Multiple Sclerosis Research Studies (94 papers), Cannabis and Cannabinoid Research (39 papers) and Immunotherapy and Immune Responses (34 papers). David Baker is often cited by papers focused on Multiple Sclerosis Research Studies (94 papers), Cannabis and Cannabinoid Research (39 papers) and Immunotherapy and Immune Responses (34 papers). David Baker collaborates with scholars based in United Kingdom, Netherlands and United States. David Baker's co-authors include Gareth Pryce, Sandra Amor, Gavin Giovannoni, Paul van der Valk, Fabìola Puentes, Klaus Schmierer, J.K. O'Neill, J.L. Turk, Jeremy R. Everett and John C. Lindon and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

David Baker

288 papers receiving 15.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Inflammation in neurodegenerative diseases

2010 1.1k citations Sandra Amor, Fabìola Puentes et al. profile →
Pharmaco-metabonomic phenotyping and personalized drug treatment

2006 621 citations T. Andrew Clayton, John C. Lindon et al. profile →
Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism

2009 565 citations T. Andrew Clayton, David Baker et al. Proceedings of the National Academy of Sciences profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David Baker United Kingdom	64	4.8k	3.6k	3.3k	3.1k	2.4k	296	15.4k
Rivka Ravid Netherlands	63	4.8k 1.0×	2.6k 0.7×	1.1k 0.3×	2.1k 0.7×	2.6k 1.1×	170	15.0k
Diego Centonze Italy	81	6.4k 1.3×	4.7k 1.3×	3.1k 0.9×	2.2k 0.7×	10.2k 4.3×	487	23.3k
Margaret A. Pericak‐Vance United States	63	7.0k 1.5×	1.3k 0.3×	788 0.2×	1.9k 0.6×	2.4k 1.0×	340	18.4k
Elio Scarpini Italy	60	3.8k 0.8×	919 0.3×	1.2k 0.4×	1.5k 0.5×	1.5k 0.6×	369	12.9k
Helga E. de Vries Netherlands	74	6.2k 1.3×	2.5k 0.7×	434 0.1×	3.0k 1.0×	1.5k 0.6×	257	16.8k
Sandra Amor Netherlands	61	3.6k 0.8×	3.1k 0.8×	404 0.1×	3.9k 1.2×	1.2k 0.5×	198	12.4k
Sven G. Meuth Germany	59	4.1k 0.9×	3.1k 0.8×	319 0.1×	2.7k 0.9×	2.5k 1.1×	561	14.0k
Yasuto Itoyama Japan	76	6.5k 1.4×	4.9k 1.3×	556 0.2×	3.0k 1.0×	4.1k 1.7×	480	20.6k
Suzanne M. de la Monte United States	70	6.3k 1.3×	1.4k 0.4×	1.3k 0.4×	593 0.2×	2.5k 1.0×	288	18.5k
Edward J. Goetzl United States	94	13.6k 2.8×	909 0.2×	2.1k 0.7×	5.8k 1.9×	3.7k 1.5×	380	26.6k

Countries citing papers authored by David Baker

Since Specialization

Citations

This map shows the geographic impact of David Baker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Baker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Baker more than expected).

Fields of papers citing papers by David Baker

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Baker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Baker. The network helps show where David Baker may publish in the future.

Co-authorship network of co-authors of David Baker

This figure shows the co-authorship network connecting the top 25 collaborators of David Baker. A scholar is included among the top collaborators of David Baker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Baker. David Baker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Giovannoni, Gavin, Louisa K. James, Julian Gold, et al.. (2025). The case for targeting latent and lytic Epstein-Barr virus infection in multiple sclerosis. Brain. 148(9). 3057–3071. 2 indexed citations

Pancholi, Jessica, Gareth Pryce, Laura J. McCormick, et al.. (2024). Delocalized quinolinium-macrocyclic peptides, an atypical chemotype for CNS penetration. Science Advances. 10(28). eado3501–eado3501. 3 indexed citations

Chung, Heaseung Sophia, Manik Garg, Ventzislava A. Hristova, et al.. (2024). Longitudinal clinical and proteomic diabetes signatures in women with a history of postgestational diabetes. JCI Insight. 10(2).

Seaton, Anthony, David Baker, Anna Karin Hedström, Lars Alfredsson, & Klaus Schmierer. (2023). Organic solvents and Multiple Sclerosis: the doubled risk dilemma. Occupational Medicine. 73(6). 300–303.

Noort, Johannes M. van, David Baker, Markus Kipp, & Sandra Amor. (2023). The pathogenesis of multiple sclerosis: a series of unfortunate events. Clinical & Experimental Immunology. 214(1). 1–17. 9 indexed citations

Marta, Mónica, et al.. (2022). Disease activity after cladribine immune reconstitution therapy: To repeat or to retreat? (P9-4.002). Neurology. 98(18_supplement). 2 indexed citations

Dobson, Ruth, et al.. (2020). Digesting science: Developing educational activities about multiple sclerosis, prevention and treatment to increase the confidence of affected families. Multiple Sclerosis and Related Disorders. 47. 102624–102624. 1 indexed citations

Ford, Brian E., Suzannah J. Harnor, Céline Cano, et al.. (2020). Chronic glucokinase activator treatment activates liver Carbohydrate response element binding protein and improves hepatocyte ATP homeostasis during substrate challenge. Diabetes Obesity and Metabolism. 22(11). 1985–1994. 10 indexed citations

Baker, David, et al.. (2019). Cost of disease modifying therapies for multiple sclerosis: Is front-loading the answer?. Journal of the Neurological Sciences. 404. 19–28. 10 indexed citations

10.

Iegre, Jessica, P. Brear, David Baker, et al.. (2019). Efficient development of stable and highly functionalised peptides targeting the CK2α/CK2β protein–protein interaction. Chemical Science. 10(19). 5056–5063. 30 indexed citations

11.

Hampton, David W., Andrea Serio, Gareth Pryce, et al.. (2013). Neurodegeneration progresses despite complete elimination of clinical relapses in a mouse model of multiple sclerosis. Acta Neuropathologica Communications. 1(1). 84–84. 25 indexed citations

12.

Puentes, Fabìola, Markus Kipp, Cordian Beyer, et al.. (2013). Characterization of immune response to neurofilament light in experimental autoimmune encephalomyelitis. Journal of Neuroinflammation. 10(1). 118–118. 9 indexed citations

13.

Sher, Falak, Sandra Amor, Wouter H. Gerritsen, et al.. (2012). Intraventricularly Injected Olig2-NSCs Attenuate Established Relapsing–Remitting EAE in Mice. Cell Transplantation. 21(9). 1883–1897. 25 indexed citations

14.

Clayton, T. Andrew, David Baker, John C. Lindon, Jeremy R. Everett, & Jeremy K. Nicholson. (2009). Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism. Proceedings of the National Academy of Sciences. 106(34). 14728–14733. 565 indexed citations breakdown →

15.

Hooper, Claudie, et al.. (2009). Differential effects of albumin on microglia and macrophages; implications for neurodegeneration following blood–brain barrier damage. Journal of Neurochemistry. 109(3). 694–705. 48 indexed citations

16.

Hepple, Russell T., et al.. (2006). Caloric Restriction Protects Mitochondrial Function with Aging in Skeletal and Cardiac Muscles. Rejuvenation Research. 9(2). 219–222. 80 indexed citations

17.

Baker, David, Andrew C. Betik, Daniel J. Krause, & Russell T. Hepple. (2006). No Decline in Skeletal Muscle Oxidative Capacity With Aging in Long-Term Calorically Restricted Rats: Effects Are Independent of Mitochondrial DNA Integrity. The Journals of Gerontology Series A. 61(7). 675–684. 71 indexed citations

18.

Pryce, Gareth, Gavin Giovannoni, & David Baker. (2003). Mifepristone or inhibition of 11β-hydroxylase activity potentiates the sedating effects of the cannabinoid receptor-1 agonist Δ(9)-tetrahydrocannabinol in mice. Neuroscience Letters. 341(2). 164–166. 21 indexed citations

19.

Giovannoni, Gavin & David Baker. (2003). Inflammatory disorders of the central nervous system. Current Opinion in Neurology. 16(3). 347–350. 10 indexed citations

20.

Giovannoni, Gavin & David Baker. (2003). Inflammatory disorders of the central nervous system. Current Opinion in Neurology. 16(3). 347–350. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact